Ritter Pharmaceuticals Inc (RTTR)

[Mikems]

I don't believe it is generally acceptable to shuffle "inappropriate" subjects out of lab trials in clinical research or in statistical research, especially after they are approved to participate. It raises some basic questions about the validity of the research and artificially conflates outcomes and levels of significance. Investors have already shown their skepticism. In addition, some of the results appear to be weak, especially taking into account the number of positive results with placebo. All the rosiness appears to have worn off here. Lactose intolerance, as multiply - defined as it has been over the years - defies categorization as a specific disease in the way that most are labeled. One may as well swallow the placebo.